Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 PSQI total and component scores throughout the study (mean ± sd) (ES: effect sizes)

From: Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study

  baseline week 6 week 12 week 18 week 24 P
Total scores 16.0 ± 3.2 12.4 ± 4.0*** 11.0 ± 4.6*** 11.2 ± 4.4*** 11.1 ± 5.1*** <0.0001
ES   1.19 1.56 1.50 1.53  
Sleep quality 2.54 ± 0.5 1.67 ± 0.8*** 1.46 ± 0.8*** 1.44 ± 0.8*** 1.53 ± 0.9*** <0.0001
ES   1.74 2.16 2.20 2.02  
Sleep latency 2.51 ± 0.7 2.10 ± 0.9 1.80 ± 1.1*** 2.08 ± 1.0* 1.87 ± 1.0*** <0.0001
ES   0.59 0.99 0.61 0.89  
Sleep duration 2.56 ± 0.6 1.90 ± 1.0*** 1.56 ± 1.1*** 1.51 ± 1.2*** 1.54 ± 1.2*** <0.0001
ES   1.10 1.66 1.75 1.72  
Sleep efficiency 2.62 ± 0.7 1.92 ± 1.2*** 1.72 ± 1.3*** 1.69 ± 1.2*** 1.62 ± 1.2*** <0.0001
ES   1.00 1.27 1.33 1.41  
Sleep disturbance 2.33 ± 0.5 1.97 ± 0.6 1.85 ± 0.6** 1.97 ± 0.7 1.44 ± 1.0*** <0.0001
ES   0.72 0.90 0.72 1.68  
Sleep medications 1.41 ± 1.4 0.82 ± 1.3 0.51 ± 1.1** 0.62 ± 1.2* 0.72 ± 1.2* = 0.0028
ES   0.42 0.62 0.56 0.48  
Daytime dysfunction 2.28 ± 0.6 2.00 ± 0.9 1.95 ± 0.9 1.92 ± 0.9 1.92 ± 1.0 = 0.0454
ES   0.47 0.51 0.55 0.55  
  1. *: p < 0.05, **: p < 0.01, and ***: p < 0.001 in relation to baseline (Tukey's post-test). Bold: large effect sizes.